Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Short implants could simplify tooth replacement

NCT ID NCT04237545

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 5 times

Summary

This study tested whether shorter dental implants work as well as standard-length ones for replacing missing back teeth. 106 adults received either a short or standard implant and were followed for 4 years. The goal was to see if the short implants kept bone stable and stayed securely in place.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
T3 short dental implant (device)
What this could lead to
If successful, this could offer a less invasive option for replacing missing back teeth, potentially avoiding the need for bone grafting.
What could go wrong
This is a completed study with 106 participants, so results are limited in size. Short implants may not be as stable as standard ones in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

106 people

The number who actually took part.

Started

Oct 2019

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients of either sex and at least 18 years of age 2. Patients for whom a decision has already been made to use a dental implant for the restoration of existing partial edentulism in the posterior mandible or maxilla. 3. Prior extracted sites (at least 4 months after extraction) preferred; immediate extractions allowed 4. Splinting to a natural tooth is allowed for the short length (test) implants 5. Intact buccal table as verified by CBCT or during surgery. If absent, patient should be excluded from enrollment in the study. 6. Presence of opposing dentition (antagonist) that will allow for functional occlusion. 7. The site intended for implant placement should have a minimum amount of keratinized gingiva of 2mm and a sufficient vertical bone height (8 - 10 mm in the maxilla; 10mm in the mandible); a short implant (as determined by randomization) will be placed without the need for augmentation except for minor dehiscence, which can be augmented with autogenous bone chips to improve soft tissue attachment. If site was randomized to long length implant (control) (with a minimum of 8mm vertical bone height in the maxilla or less than 10 mm in the mandible) it will have simultaneous augmentation procedure (sinus elevation in the maxilla; vertical ridge augmentation in the mandible). 8. The site intended for implant placement should have approximately 1.5mm buccal-lingual distance on each side in order to allow for wide platform implant (5 and 6mm diameter). 9. Patients must be physically able to tolerate conventional surgical and restorative procedures. 10. Patients who provide a signed informed consent 11. Patients who agree to be evaluated for each study visit. Exclusion Criteria: 1. Patients with known systemic diseases such as uncontrolled diabetes, endocrine disease, heart disease, immuno-compromised, or mental disorders. 2. Patients with current use of non-steroidal anti-inflammatory drugs, bisphosphonates or corticosteroid treatments. 3. Patients with active infection or severe inflammation in the areas intended for treatment. 4. Patients with a \> 10 cigarette per day smoking habit. 5. Patients with a history of therapeutic radiation to the head or jaw. 6. Patients receiving other dental treatment(s) during the study that could have a negative impact on the healing phase of the study treatment sites. 7. Patients who are known to be pregnant at the screening visit or planning to become pregnant within 6 months of study enrollment. 8. Patients with evidence of severe parafunctional habits such as bruxing or clenching. 9. Patients who have previously failed dental implants at the site intended for study implant placement 10. Patients with HIV or Hepatitis infection 11. Patients with a history of generalized severe chronic periodontal disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Edentulous jaw are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Jaw, Edentulous

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dr. Jordi Gargallo

    Tarragona, Catalonia, 43002, Spain

  • Dr. Stefano Sivolella

    Padova, 35127, Italy

  • Dr. Suheil Boutros

    Dearborn Heights, Michigan, 48127, United States

  • Dr. Xiaozhe Han

    Boston, Massachusetts, 02111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.